---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-096092"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2022-08-30T23:59:59+00:00"
generated_at: "2026-06-23T19:26:33.866234+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# VYNE receives Nasdaq extension to Feb 2023; pays Tay £850k for BETi compounds

## Summary
- Nasdaq granted 180-day extension until Feb 27, 2023 to regain minimum $1.00 bid price for 10 consecutive days.
- VYNE common stock transferred from Nasdaq Global Select to Capital Market, effective Aug 31, 2022.
- VYNE paid Tay Therapeutics £850,000 after receipt of Oral BETi Compounds meeting specified molecular profile.
- Company expects to exercise exclusive option on Oral BETi Compounds by end of 2022, before Feb 28, 2023 expiry.
- If compliance not regained by Feb 27, 2023, Nasdaq will delist; VYNE may appeal or consider reverse stock split.

## SEC filing metadata
- accession: 0001104659-22-096092
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2022-08-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465922096092/0001104659-22-096092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465922096092/tm2224821d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-096092
- JSON: https://secwatch.observer/filing/0001104659-22-096092.json
- Plain text: https://secwatch.observer/filing/0001104659-22-096092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.